Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study

Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes

(2022) Grant M Jones et al.   JOURNAL OF PSYCHOPHARMACOLOGY

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

(2022) Grant M Jones et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension

(2022) Grant M Jones et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

(2021) Otto Simonsson et al.   HYPERTENSION

The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects

(2021) Malin Vedøy Uthaug et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Use and abuse of dissociative and psychedelic drugs in adolescence

(2021) M.L. Shawn Bates et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Associations between lifetime classic psychedelic use and cardiometabolic diseases

(2021) Otto Simonsson et al.   Scientific Reports

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

(2020) Gabrielle I Agin-Liebes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

(2020) Albert Garcia-Romeu et al.   Frontiers in Psychiatry

Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics

(2020) James D. Sexton et al.   Frontiers in Psychiatry

Pharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer?

(2020) Laura Brandt et al.   ADDICTION

If there were an effective pharmacotherapy for cocaine use disorder, what would it do?

(2020) Steven Shoptaw et al.   ADDICTION

Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers

(2019) David Erritzoe et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cessation and reduction in alcohol consumption and misuse after psychedelic use

(2019) Albert Garcia-Romeu et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial

(2019) Elias Dakwar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Psychedelics and the essential importance of context

(2018) Robin L Carhart-Harris et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study

(2018) E. Dakwar et al.   NEUROPHARMACOLOGY

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

(2018) Matthew W. Johnson et al.   NEUROPHARMACOLOGY

Environmental, genetic and epigenetic contributions to cocaine addiction

(2018) R. Christopher Pierce et al.   NEUROPSYCHOPHARMACOLOGY

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

(2018) Paulo Cesar Ribeiro Barbosa et al.   Frontiers in Psychiatry

Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis

(2018) Franco De Crescenzo et al.   PLOS MEDICINE

Pharmacokinetic And Pharmacodynamic Aspects Of Peyote And Mescaline: Clinical And Forensic Repercussions

(2018) Ricardo Jorge Dinis-Oliveira et al.   Current Molecular Pharmacology

The relationships of classic psychedelic use with criminal behavior in the United States adult population

(2017) Peter S Hendricks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The association of psychedelic use and opioid use disorders among illicit users in the United States

(2017) Vincent D Pisano et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial

(2016) E Dakwar et al.   MOLECULAR PSYCHIATRY

Classic hallucinogens in the treatment of addictions

(2016) Michael P. Bogenschutz et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Powder cocaine and crack use in the United States: An examination of risk for arrest and socioeconomic disparities in use

(2015) Joseph J. Palamar et al.   DRUG AND ALCOHOL DEPENDENCE

Psilocybin, psychological distress, and suicidality

(2015) Peter S Hendricks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

(2015) Peter S Hendricks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

(2015) Michael P Bogenschutz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Substance Use Disorder Among People With First-Episode Psychosis: A Systematic Review of Course and Treatment

(2015) Jennifer P. Wisdom et al.   PSYCHIATRIC SERVICES

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

(2014) Matthew W Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

(2012) Teri S Krebs et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Neurovascular complications of cocaine

(2010) M. Daras et al.   ACTA NEUROLOGICA SCANDINAVICA

Human hallucinogen research: guidelines for safety

(2008) MW Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

(2008) RR Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY